ReShape Lifesciences: Merger, Asset Sale, and Corporate Reshuffle

ReShape Lifesciences (RSLS) has shared an update.

ReShape Lifesciences Inc. is set to undergo significant corporate restructuring through a merger and asset sale. The company has finalized plans to merge with Vyome Therapeutics Inc., resulting in Vyome becoming a subsidiary of ReShape. Concurrently, ReShape will sell the majority of its assets, excluding cash, to Ninjour Health International Limited for $5.16 million, adjusting the price based on accounts receivable and payable. Additionally, ReShape has reached an agreement with its series C preferred stockholders to reduce their liquidation preference contingent upon the merger and asset sale completion. As part of the financing arrangements related to these transactions, investors have agreed to purchase up to $7.3 million in securities of the involved companies, with terms favoring the investors in the event of the merger’s successful completion.

See more insights into RSLS stock on TipRanks’ Stock Analysis page.